Harris R I, Stuart J
Lancet. 1979 Jan;1(8107):93-4. doi: 10.1016/s0140-6736(79)90075-8.
27 adults with haemophilic arthropathy infused freeze-dried factor-VIII concentrate at a mean initial dose of 7.3 and 5.5 units/kg, respectively, during two successive 6-month periods of home therapy. A single infusion at either dosage level successfully terminated over 80% of bleeds. A 32% reduction in use of concentrate was achieved at the lower dose, with a cost saving equivalent to pounds 30 000 per annum and with no apparent short-term clinical disadvantage. Thus low-dose therapy can be successfully applied to severely affected adult patients with established haemophilic arthropathy.
27名患有血友病性关节病的成年人在两个连续的6个月家庭治疗期间，分别以平均初始剂量7.3单位/千克和5.5单位/千克输注冻干因子VIII浓缩物。两种剂量水平的单次输注均成功终止了超过80%的出血。较低剂量时浓缩物的使用量减少了32%，每年节省成本相当于30000英镑，且没有明显的短期临床劣势。因此，低剂量疗法可成功应用于患有已确诊血友病性关节病的重度成年患者。
